Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.92B +122.7% |
| Revenue (ttm) | 67.67M +16.9% |
| Net Income | -412.69M |
| EPS | -3.81 |
| Shares Out | 139.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,043,553 |
| Open | 13.78 |
| Previous Close | 13.85 |
| Day's Range | 13.42 - 14.07 |
| 52-Week Range | 6.83 - 28.25 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 20.02 (+46.03%) |
| Earnings Date | May 19, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $20.02, which is an increase of 46.03% from the latest price.
News
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
20:06 EDT Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today
23:21 EDT Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics (NTLA) today
Unusually active option classes on open April 29th
Unusual total active option classes on open include: Intellia Therapeutics (NTLA), Teva (TEVA), FuelCell (FCEL), iShares 20 Year Treasury Bond ETF (TLT), BigBearai Holdings (BBAI), Qualcomm (QCOM), Jo...
Intellia Therapeutics 16.7M share Secondary priced at $10.75
The deal size was increased to $180M in common stock from $150M in common stock. Jefferies, Goldman Sachs and Citi acted as joint book running managers for the offering. Published
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today
20:06 EDT Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics (NTLA) today
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio move on Monday, April 27, 2026, as shown in ARK’s daily fund disclosures. The firm continued to reduce its position in the ...
Intellia Therapeutics price target raised to $13 from $7 at Baird
Baird raised the firm’s price target on Intellia Therapeutics (NTLA) to $13 from $7 and keeps a Neutral rating on the shares. The firm updated its model following positive pivotal
Intellia Therapeutics price target raised to $58 from $48 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Intellia Therapeutics (NTLA) to $58 from $48 and keeps a Buy rating on the shares. The firm updated its model
Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $8 and keeps a Sell rating on the shares.
Intellia Therapeutics price target raised to $30 from $28 at Citizens
Citizens raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $28 and keeps an Outperform rating on the shares. Intellia’s Phase 3 HAELO outcome are positive for
Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today
20:09 EDT Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics announces $150M common stock offering
Intellia Therapeutics (NTLA) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the proposed offering are to
Intellia Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics price target raised to $30 from $27 at Chardan
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $27 and keeps a Buy rating on the shares. The company this morning reported positive results from
Intellia Therapeutics price target raised to $35 from $29 at Leerink
Leerink raised the firm’s price target on Intellia Therapeutics (NTLA) to $35 from $29 and keeps an Outperform rating on the shares. Following the company’s topline HAELO results and conference
Intellia Therapeutics price target raised to $20 from $19 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Intellia Therapeutics (NTLA) to $20 from $19 and keeps a Neutral rating on the shares. Phase 3 HAELO data support
Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Intellia Therapeutics (NTLA) to $15 from $11 and keeps an Equal Weight rating on the shares after the company reported that Lonvo-z
Intellia Therapeutics price target raised to $13 from $7 at Baird
Baird analyst Jack Allen raised the firm’s price target on Intellia Therapeutics (NTLA) to $13 from $7 and keeps a Neutral rating on the shares.
Intellia Therapeutics says HAELO trial met primary, secondary endpoints
Intellia Therapeutics (NTLA) announced topline results from the global Phase 3 HAELO clinical trial of lonvo-z in hereditary angioedema . Designed as a one-time treatment that is administered in an
Intellia Therapeutics initiates rolling BLA submission for lonvo-z for HAE
Intellia Therapeutics (NTLA) announced it has initiated a rolling submission of a biologics license application to the U.S. Food and Drug Administration seeking approval of lonvo-z for hereditary angi...
Intellia Therapeutics Transcript: Study result
The phase III HAELO trial showed that a single dose of lonvo-z, an in vivo CRISPR-based gene-editing therapy, led to an 87% reduction in HAE attack rates and 62% of patients being attack- and therapy-free at six months, with a favorable safety profile. Early crossover data suggest further improvements over time. Additional long-term data and subgroup analyses will be presented at EAACI.
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.